Trials / Completed
CompletedNCT01056471
Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis
Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and feasibility of regenerative therapy with mesenchymal stem cells from adipose tissue, administered intravenously in patients with secondary progressive multiple sclerosis who do not respond to treatment.
Conditions
- Autoimmune Diseases
- Immune System Diseases
- Demyelinating Diseases
- Nervous System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Autologous mesenchymal stem cells from adipose tissue. | Intravenous infusion of autologous mesenchymal stem cells.Dose:4\*10e6 cells/Kg. |
| OTHER | Autologous mesenchymal stem cells from adipose tissue. | Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2012-06-01
- Completion
- 2015-06-01
- First posted
- 2010-01-26
- Last updated
- 2015-08-07
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01056471. Inclusion in this directory is not an endorsement.